Sun.Mar 17, 2024

article thumbnail

Aging And Schizophrenia Share Striking Similarities in 2 Types of Brain Cells

AuroBlog - Aurous Healthcare Clinical Trials blog

Similar genetic changes in two different types of brain cells may contribute to cognitive impairment in schizophrenia and aging. US researchers examined gene expression in more than a million brain cells collected post-mortem from 191 donors.

article thumbnail

Contineum, a startup born from a Roche buyout, files for IPO

Bio Pharma Dive

The biotech, formed as a successor to a company Roche acquired in 2018, has two drugs in clinical testing for neurological and immune diseases.

Drugs 188
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DoP releases new UCPMP for pharma and medical devices companies

AuroBlog - Aurous Healthcare Clinical Trials blog

The Department of Pharmaceuticals (DoP) has issued a new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, permitting pharma companies to provide brand reminders such as informational and education items and free samples to medical professionals with restrictions on sample packs and total value.

article thumbnail

5 Steps to Find the Best Dentist in Whittier for Your Needs

Pharma Mirror

Finding the right dentist in Whittier can be daunting, but it’s crucial for maintaining oral health. From routine check-ups to specialized treatments, a reliable dentist can make all the difference. In this article, we’ll walk you through five essential steps to help you find the best dentist in Whittier for your specific needs. So, let’s dive right in!

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

AstraZeneca Caps US Inhaler Out-of-Pocket Costs on Heels of Boehringer

BioSpace

With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.

108
108
article thumbnail

The Winning Formula For Life Sciences: Salesforce Life Sciences Cloud And Cloudbyz eClinical Solutions Collaboration

Cloudbyz

In the dynamic world of life sciences, where innovation is paramount, the integration of cutting-edge technologies is crucial for accelerating clinical operations and driving breakthroughs in healthcare. Salesforce’s recent announcement of its Life Sciences Cloud marks a significant stride towards this goal. Combined with Cloudbyz eClinical which is built natively on the Salesforce platform, this collaboration promises to revolutionize the way life science organizations manage their clinic

More Trending

article thumbnail

New tentative approval for Zydus Pharms drug empagliflozin;linagliptin;metformin hydrochloride

Drug Patent Watch

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

Drugs 59
article thumbnail

Pfizer to Lower Its Stake in GSK Consumer Health Spinoff Haleon

BioSpace

Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.

Sales 88
article thumbnail

New tentative approval for Sandoz Inc drug rifaximin

Drug Patent Watch

Rifaximin is the generic ingredient in one branded drug marketed by Salix Pharms and is included in one NDA. There are twenty-nine patents protecting this compound.

Drugs 59
article thumbnail

AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need

BioSpace

AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.

87
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Pharmaceutical companies with the most ‘New Chemical Entity’ drugs

Drug Patent Watch

Five years of exclusivity is provided for drugs which do not contain active molecules that have appeared in previously-approved drugs.

Drugs 59
article thumbnail

FDA Action Alert: Orchard, ITF, Merck and More

BioSpace

The FDA will close out a hectic month of March with a flurry of target action dates, including ones for lymphoma and CKD anemia treatments.

89
article thumbnail

Science and Sex

JAMA Internal Medicine

This Viewpoint examines why investigators should address women’s health in all biomedical and health-related research.

article thumbnail

GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase I.

BioSpace

New late-stage trial results for GSK’s Jemperli show improved overall and progression-free survival in a broader range of endometrial cancer patients, which could lead to a potential label expansion.

Trials 72
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

J&J-Backed Contineum Unveils IPO Plans to Advance MS Pipeline

BioSpace

Contineum Therapeutics joined the biotech 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.

Trials 70
article thumbnail

Opinion: I Know I Want to Implement AI in My Company’s R&D. What Now?

BioSpace

Knowing that you want to integrate AI is one thing—but how do you actually do it? For biotech companies kickstarting their generative AI journey, here are four things to consider.

69